Eli Lilly is hoping new data from its Taltz (ixekizumab) could give it another potentially lucrative indication and put pressure on Novartis’ rival IL-17a drug, Cosentyx.
Sanofi is one of several pharma companies that is on a quest to use digital health to make trials cheaper and more effective – and has found another partner to help it.
